ReviewOncotarget2018
Active ginseng components in cognitive impairment: Therapeutic potential and prospects for delivery and clinical study.
Review in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Valorization of Panax ginseng residues: Functional fiber development through cross-linking combined with ultrasonication.Ultrasonics sonochemistry · 2026Article
- Panax-derived ginsenosides in diabetes-associated cognitive dysfunction: mechanistic evidence and translational barriers.Frontiers in endocrinology · 2026Review
- The therapeutic role of ginseng in promoting hippocampal neurogenesis and ameliorating cognitive function following whole brain radiotherapy in rats.Metabolic brain disease · 2025Article
- The role of Panax ginseng in neurodegenerative disorders: mechanisms, benefits, and future directions.Metabolic brain disease · 2025Review
- Network analysis andFrontiers in pharmacology · 2025Article
- Combining Network Pharmacology and Transcriptomic Strategies to Explore the Pharmacological Mechanism of Total Ginsenoside Ginseng Root and Its Impact on Antidepressant Effects.International journal of molecular sciences · 2024Article
- Ginseng root-derived exosome-like nanoparticles protect skin from UV irradiation and oxidative stress by suppressing activator protein-1 signaling and limiting the generation of reactive oxygen species.Journal of ginseng research · 2024Article
- Progress of Ginsenoside Rb1 in neurological disorders.Frontiers in pharmacology · 2024Review
- Pharmaceutical and pharmacological studies of Shen Ma Yi Zhi granule for prevention of vascular dementia: A review.Frontiers in neuroscience · 2022Review
- Pharmacological insights into Merremia vitifolia (Burm.f.) Hallier f. leaf for its antioxidant, thrombolytic, anti-arthritic and anti-nociceptive potential.Bioscience reports · 2021Article
- Evolution of the adaptogenic concept from traditional use to medical systems: Pharmacology of stress- and aging-related diseases.Medicinal research reviews · 2021Review
- Biological efficacy of zinc oxide nanoparticles against diabetes: a preliminary study conducted in mice.Bioscience reports · 2020Article
- Efficacy ofPharmaceuticals (Basel, Switzerland) · 2020Article
- Review
- Ginsenoside Rb1 Improves Cognitive Impairment Induced by Insulin Resistance through Cdk5/p35-NMDAR-IDE Pathway.BioMed research international · 2020Article
- Constitutive and Stress-Induced Psychomotor Cortical Responses to Compound K Supplementation.Frontiers in neuroscience · 2020Article
- Potential Therapeutic Targets of Quercetin and Its Derivatives: Its Role in the Therapy of Cognitive Impairment.Journal of clinical medicine · 2019Review
- The Methanol Extract ofAntioxidants (Basel, Switzerland) · 2019Article
- Chemical Structures and Pharmacological Profiles of Ginseng Saponins.Molecules (Basel, Switzerland) · 2019Review
- Taurine and its analogs in neurological disorders: Focus on therapeutic potential and molecular mechanisms.Redox biology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive impairment is a state that affects thinking, communication, understanding, and memory, and is very common in various neurological disorders. Among many factors, age-related cognitive decline is an important area in mental health research. Research to find therapeutic medications or supplements to treat cognitive deficits and maintain cognitive health has been ongoing. Ginseng and its active components may have played a role in treating chronic disorders. Numerous preclinical studies have confirmed that ginseng and its active components such as ginsenosides, gintonin, and compound K are pharmacologically efficacious in different models of and are linked to cognitive impairment. Among their several roles, they act as an anti-neuroinflammatory and help fight against oxidative stress and modulate the cholinergic signal. These roles may be involved in enhancing cognition and attenuating impairment. There have been some clinical studies on the activity of ginseng in cognitive impairment, but many ginseng species and active compounds remain to be investigated. In addition, new formulations of active ginseng components such as nanoparticles and liposomes could be used for preclinical and clinical models of cognitive impairment. Here, we discuss the therapeutic potential of active ginseng components in cognitive impairment and their chemistry and pharmacokinetics and consider prospects for their delivery and clinical study with respect to cognitive impairment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.